Frank B Furnari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8095396/publications.pdf

Version: 2024-02-01

103	14,004	24978 57	31759 101
papers	citations	h-index	g-index

112	112	112	19474
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development, 2007, 21, 2683-2710.	2.7	1,952
2	Malignant glioma: genetics and biology of a grave matter. Genes and Development, 2001, 15, 1311-1333.	2.7	1,064
3	PHLPP: A Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth. Molecular Cell, 2005, 18, 13-24.	4.5	796
4	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature, 2017, 543, 122-125.	13.7	530
5	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	2.7	463
6	Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA. Science, 2014, 343, 72-76.	6.0	460
7	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes and Development, 2010, 24, 1731-1745.	2.7	454
8	Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. Clinical Cancer Research, 2006, 12, 5064-5073.	3.2	440
9	Heterogeneity Maintenance in Glioblastoma: A Social Network. Cancer Research, 2011, 71, 4055-4060.	0.4	386
10	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12867-12872.	3.3	365
11	Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature, 2019, 575, 699-703.	13.7	343
12	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews Cancer, 2015, 15, 302-310.	12.8	305
13	Cancer-Associated Protein Kinase C Mutations Reveal Kinaseâ€™s Role as Tumor Suppressor. Cell, 2015, 160, 489-502.	13.5	285
14	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell, 2016, 30, 683-693.	7.7	237
15	EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. Cancer Research, 2009, 69, 4252-4259.	0.4	232
16	PCAF Modulates PTEN Activity. Journal of Biological Chemistry, 2006, 281, 26562-26568.	1.6	183
17	A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma. PLoS Genetics, 2009, 5, e1000374.	1.5	179
18	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell, 2015, 60, 307-318.	4.5	161

#	Article	IF	Citations
19	NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature, 2019, 569, 570-575.	13.7	153
20	Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Research, 2002, 62, 6764-9.	0.4	152
21	MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression. Molecular Cancer Research, 2011, 9, 1100-1111.	1.5	146
22	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 2018, 34, 163-177.e7.	7.7	145
23	Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6505-6510.	3.3	141
24	Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. Journal of Clinical Investigation, 2011, 121, 161-173.	3.9	141
25	Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. Cancer Research, 2009, 69, 6889-6898.	0.4	136
26	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism, 2019, 30, 525-538.e8.	7.2	130
27	Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget, 2014, 5, 882-893.	0.8	127
28	Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro-Oncology, 2016, 18, 914-918.	0.6	117
29	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 2011, 30, 5-12.	4.9	116
30	A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma. PLoS Genetics, 2013, 9, e1003253.	1.5	114
31	Immunohistochemical analysis of the mutant epidermal growth factor, Î”EGFR, in glioblastoma. Brain Tumor Pathology, 2004, 21, 53-56.	1.1	112
32	Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2703-2706.	3.3	109
33	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell, 2008, 13, 355-364.	7.7	109
34	Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex. Molecular and Cellular Biology, 2004, 24, 8981-8993.	1.1	108
35	Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRÎ±-stimulated glioma tumorigenesis in mice and humans. Journal of Clinical Investigation, 2011, 121, 4670-4684.	3.9	105
36	Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptorâ€“Specific Antibody Generates Enhanced Antitumor Activity. Clinical Cancer Research, 2005, 11, 6390-6399.	3.2	103

#	Article	IF	Citations
37	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene, 1999, 18, 3936-3943.	2.6	102
38	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell, 2019, 35, 504-518.e7.	7.7	102
39	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14164-14169.	3.3	97
40	PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications, 2017, 8, 15223.	5.8	94
41	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5768-5773.	3.3	91
42	In vitroloss of heterozygosity targets thePTEN/MMAC1gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9418-9423.	3.3	90
43	Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3018-3023.	3.3	88
44	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis, 2013, 34, 725-738.	1.3	86
45	The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(â€”). Cancer Research, 2016, 76, 2954-2963.	0.4	84
46	EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. Journal of Clinical Investigation, 2014, 124, 3741-3756.	3.9	82
47	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 370-375.	3.3	79
48	IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene, 2000, 19, 2687-2694.	2.6	75
49	The Protein Tyrosine Phosphatase TCPTP Suppresses the Tumorigenicity of Glioblastoma Cells Expressing a Mutant Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 2001, 276, 46313-46318.	1.6	66
50	The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell, 2006, 9, 379-390.	7.7	65
51	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. Journal of Experimental Medicine, 2011, 208, 2657-2673.	4.2	65
52	The Efficacy of Epidermal Growth Factor Receptorâ€“Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. Clinical Cancer Research, 2007, 13, 1911-1925.	3.2	64
53	Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach. Cell Cycle, 2007, 6, 2750-2754.	1.3	63
54	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2616-2621.	3.3	63

#	Article	IF	Citations
55	Integrin Î±vÎ²5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy. Cell Reports, 2020, 30, 969-983.e4.	2.9	63
56	Blockade of a Laminin-411â€“Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. Cancer Research, 2019, 79, 1239-1251.	0.4	61
57	PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4339-4344.	3.3	60
58	Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy. PLoS ONE, 2010, 5, e10767.	1.1	59
59	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 2014, 74, 1429-1439.	0.4	59
60	Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15984-15989.	3.3	54
61	Glioblastoma cellular cross-talk converges on NF-ÎºB to attenuate EGFR inhibitor sensitivity. Genes and Development, 2017, 31, 1212-1227.	2.7	53
62	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Science Signaling, 2014, 7, pe15.	1.6	50
63	YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. Oncogene, 2018, 37, 5492-5507.	2.6	49
64	A Urokinase Receptorâ€“Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. Cancer Research, 2015, 75, 394-404.	0.4	48
65	The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas. Clinical Cancer Research, 2013, 19, 5722-5732.	3.2	46
66	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10009-10018.	3.3	46
67	Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nature Communications, 2020, 11, 550.	5.8	45
68	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biology and Medicine, 2013, 10, 192-205.	1.4	45
69	Decoy for microRNAs. Nature, 2010, 465, 1016-1017.	13.7	44
70	Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of Î”EGFR. Journal of Proteome Research, 2011, 10, 1343-1352.	1.8	44
71	Nuclear EGFRvIIIâ€“STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bclâ€“XL promoter. International Journal of Cancer, 2013, 132, 509-520.	2.3	41
72	Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Molecular BioSystems, 2010, 6, 1227.	2.9	40

#	Article	IF	Citations
73	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of Controlled Release, 2016, 244, 14-23.	4.8	40
74	SETA: A novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-Oncology, 2000, 2, 6-15.	0.6	38
75	Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances, 2021, 7, .	4.7	38
76	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports, 2021, 37, 109957.	2.9	38
77	Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science, 2011, 124, 2938-2950.	1.2	35
78	Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. EBioMedicine, 2020, 55, 102736.	2.7	35
79	PI3KÎ³ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	33
80	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. Autophagy, 2018, 14, 1845-1846.	4.3	30
81	SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability. Genes and Development, 2020, 34, 1316-1329.	2.7	30
82	Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development. Neuro-Oncology, 2018, 20, 1310-1320.	0.6	27
83	PTEN: A Novel Anti-oncogenic Function Independent of Phosphatase Activity. Cell Cycle, 2005, 4, 540-542.	1.3	26
84	FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene, 2018, 37, 1386-1398.	2.6	25
85	PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. Neuro-Oncology, 2021, 23, 1072-1086.	0.6	23
86	Molecular Biology of Malignant Degeneration of Astrocytoma. Pediatric Neurosurgery, 1996, 24, 41-49.	0.4	16
87	Escape from targeted inhibition: The dark side of kinase inhibitor therapy. Cell Cycle, 2010, 9, 1661-1662.	1.3	12
88	Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. Neuro-Oncology, 2021, 23, 400-411.	0.6	11
89	Intron 1â€“Mediated Regulation of EGFR Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. Molecular Cancer Research, 2019, 17, 2208-2220.	1.5	10
90	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget, 2015, 6, 11751-11767.	0.8	9

#	Article	IF	Citations
91	TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo. Neuro-Oncology, 2022, 24, 2063-2075.	0.6	9
92	EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration. Journal of Cell Science, 2020, 133, .	1.2	8
93	Genome Engineering Evolves Brain Tumor Modeling. Neurologia Medico-Chirurgica, 2020, 60, 329-336.	1.0	7
94	Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. Journal of Visualized Experiments, 2018, , .	0.2	4
95	A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. Frontiers in Oncology, 2021, 11, 652133.	1.3	4
96	The impact of phosphorylated PTEN at threonine 366 on cortical connectivity and behaviour. Brain, 2022, 145, 3608-3621.	3.7	4
97	The PTEN/PI3 Kinase Pathway in Human Glioma. , 2009, , 315-357.		3
98	When less is more: Gaining power through gene rearrangement of amplifiedEGFR. Oncotarget, 2019, 10, 2116-2117.	0.8	1
99	ATPS-86MUTATIONS IN THE EGF RECEPTOR EXTRACELLULAR DOMAIN REVEAL AN UNTETHERED TRANSITIONAL STATE WHICH MEDIATES mAb806 BINDING. Neuro-Oncology, 2015, 17, v37.3-v37.	0.6	0
100	CBIO-04DAXX INHIBITION SUPPRESSES TUMOR GROWTH IN PTEN-DEFICIENT HUMAN GLIOBLASTOMAS. Neuro-Oncology, 2015, 17, v55.4-v55.	0.6	0
101	HGG-12. HUMAN IPSC-DERIVED H3.3K27M NEUROSPHERES: A NOVEL MODEL FOR INVESTIGATING DIPG PATHOGENESIS AND DRUG RESPONSE. Neuro-Oncology, 2021, 23, i19-i20.	0.6	0
102	OTEH-9. scRNA sequencing of proneural GBM avatar model reveals acquisition of oncogenic transcriptional programming and infers a developmental path towards a genomically unstable state. Neuro-Oncology Advances, 2021, 3, ii12-ii12.	0.4	0
103	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. Journal of Cell Biology, 2011, 195, i10-i10.	2.3	0